Skip to content

New medicine Finerenone approved for market launch. There’s new hope for diabetic kidney disease.

New medicine Finerenone approved for market launch.

Whether it’s type 1 or type 2 diabetes, 30-40% of patients will experience kidney damage. Diabetic kidney disease is one of the complications of diabetes, a systemic microvascular condition. In type 1 diabetes, which is more common in younger people, diabetic kidney disease typically develops around ten years after the diabetes diagnosis. In the case of type 2 diabetes, the duration may be shorter, likely due to the older age of most type 2 diabetes patients and their multiple underlying health conditions.

kidney 2

The early symptoms of diabetic kidney disease are often very subtle. Without additional tests, it’s typically when noticeable symptoms appear that the condition has already progressed to the fourth stage of chronic kidney disease (marked by significant proteinuria, or visible foamy urine). The key to treating diabetic kidney disease is to control blood sugar levels and protect kidney function.

Common medications for diabetic kidney disease

Common medications for diabetic kidney disease include drugs like the glucagon-like peptide-1 (GLP-1) agonists, acarbose, as well as angiotensin-converting enzyme inhibitors (ACE inhibitors), which can help regulate various markers in diabetic kidney disease patients and protect kidney function. Treatments may also involve hemodialysis and kidney transplantation.

As for the use of mineralocorticoid receptor antagonists (such as spironolactone and eplerenone) in the treatment of diabetic kidney disease, while these drugs can block the excessive activation of mineralocorticoid receptors, which might be beneficial for kidney function recovery, their use in treating diabetic kidney disease is not common. The reasons for this could be related to potential side effects and the need for careful monitoring, as well as the availability of other well-established treatments. It’s important for healthcare professionals to assess the individual patient’s condition and determine the most appropriate treatment plan based on their specific needs and risks.

medications for diabetic kidney disease

Using spironolactone as an example, especially when used as a standalone therapy, in combination with a high potassium diet, or in the presence of kidney dysfunction, oliguria (low urine output), or anuria (no urine output), it can lead to hyperkalemia, which is high levels of potassium in the blood. To address hyperkalemia, some have suggested combining spironolactone with thiazide diuretics, but the results have not been consistently satisfactory, and hyperkalemia still occurs in a significant percentage of cases, ranging from 8.6% to 26%. This is why spironolactone is rarely used in the treatment of diabetic kidney disease, as the risk of hyperkalemia is a significant concern.

Effective Medicine diabetic kidney disease

Nonetheless, there is indeed a medication known as finerenone that has emerged to address this issue. Finerenone has broken this deadlock and offers hope for the treatment of diabetic kidney disease. Its first approved indication is for chronic kidney disease in type 2 diabetes patients. So, while traditional mineralocorticoid receptor antagonists like spironolactone may pose challenges in managing diabetic kidney disease due to the risk of hyperkalemia, finerenone has shown promise in this regard and has gained approval for this specific use.

LUCIFINE Finerenone Tablets
LUCIFINE Finerenone Tablets

Finerenone improves chronic kidney disease associated with type 2 diabetes

Finerenone, developed by the German pharmaceutical company Bayer, is a new-generation, non-steroidal, selective mineralocorticoid receptor antagonist. It is also known as finerenone or finerenone. It was approved for market launch in July of the previous year.

To answer how finerenone improves chronic kidney disease related to type 2 diabetes, we first need to understand the mechanism of mineralocorticoids and their action. Mineralocorticoids are substances secreted by the zona glomerulosa of the adrenal cortex, with aldosterone being the primary representative.

Aldosterone’s target organs include the kidneys, heart, salivary glands, gastrointestinal secretory glands, and others, and it is regulated by the renin-angiotensin-aldosterone system, blood potassium ions, and blood sodium ions. When aldosterone secretion increases, its effects on the kidneys lead to increased reabsorption of sodium and water, increased excretion of potassium ions, resulting in fluid and sodium retention, hypernatremia (high sodium levels in the blood), hypokalemia (low potassium levels in the blood), and metabolic alkalosis, among other effects. This can contribute to kidney damage.

Finerenone works by selectively blocking the mineralocorticoid receptor, reducing the harmful effects of aldosterone on the kidneys and other target organs. By doing so, it helps mitigate the progression of kidney disease in type 2 diabetes patients, providing a novel approach to treating this condition.

kidney 3

Finerenone can block the actions of mineralocorticoids, such as mediating sodium reabsorption and the excessive activation of mineralocorticoid receptors in epithelial tissues like the kidneys. This mechanism helps improve chronic kidney disease related to type 2 diabetes.

Research has shown that finerenone does not exhibit activity on L-type calcium ion channels and has no significant effects on 65 different enzymes and ion channels. This research indicates that finerenone is a highly selective mineralocorticoid receptor antagonist. This high selectivity is primarily mediated through interactions with hydrogen bond donors and specific residues like Ala773 and Ser810 in mineralocorticoid receptors.

kidney 4

When finerenone is administered orally, it can be fully absorbed by the body. After undergoing a series of metabolic reactions, its absolute bioavailability can reach 44%. Finerenone reaches its maximum plasma concentration within 0.5-1.25 hours after administration and has a half-life of 2-3 hours in the body.

Precautions when using Finerenone

The question of whether it’s better to take medication before or after a meal is a common one, and it’s generally believed that taking medication after eating is more effective. But is this really the case? When it comes to finerenone, there’s no specific need to take it either before or after a meal.

Research has shown that finerenone exhibits dose-linear pharmacokinetics in a fasting state, with rapid absorption (reaching peak plasma concentration within 0.5-1 hour) and elimination (average terminal half-life ranging from 1.70 to 2.83 hours). It also demonstrates favorable pharmacokinetic characteristics when taken after a meal. This means that you can take finerenone without having to be overly concerned about whether it’s taken before or after eating.

Finerenone is primarily metabolized in the body by the CYP3A4 enzyme, with a smaller portion metabolized by the CYP2C8 enzyme. It is converted into inactive metabolites and is then excreted from the body, with approximately 80% excreted through urine and 20% through feces.

As a mineralocorticoid receptor antagonist, finerenone primarily works by affecting the actions of mineralocorticoids, particularly aldosterone, to improve kidney damage. However, it’s worth noting that aldosterone’s target organs are not limited to the kidneys; the heart is also one of its targets. While finerenone’s primary indication is for chronic kidney disease in type 2 diabetes patients, it may also have therapeutic effects on heart-related conditions due to its influence on the effects of aldosterone in the body. This is a subject of ongoing research and clinical investigation.


Finerenonenot only protects the kidneys but also protects the heart

As a new-generation mineralocorticoid receptor antagonist, finerenone not only improves chronic kidney disease resulting from type 2 diabetes but also reduces the incidence and mortality of cardiovascular diseases.

Heart failure is a chronic, complex, progressive cardiac syndrome and a major cause of morbidity and mortality in cardiovascular diseases. It is one of the two major challenges in the 21st century’s cardiovascular system. It is characterized by impaired ventricular filling and/or ejection function, leading to an inadequate cardiac output to meet the metabolic needs of the body. Typical clinical symptoms include shortness of breath, lower extremity edema, and limited physical activity.

There are numerous treatment options for heart failure. Diuretics that can control fluid retention can alleviate symptoms and slow the progression of heart failure. Angiotensin-converting enzyme inhibitors, which can reduce mortality in heart failure patients with different etiologies and severity, are also commonly prescribed. Finerenone’s ability to reduce the incidence and mortality of cardiovascular diseases suggests its potential as a valuable addition to the treatment arsenal for heart failure and other related conditions.

6 things you must know about Diabetic Kidney Disease

Despite various treatments, the incidence and mortality of heart failure remain high. Mineralocorticoid receptor antagonists are a cornerstone in the treatment of chronic heart failure, and finerenone, as a new and highly selective non-steroidal mineralocorticoid receptor antagonist, has shown promising results in the management of cardiovascular diseases.

Finerenone can reduce the levels of aldosterone in the body, which affects the binding of aldosterone to mineralocorticoid receptors in the heart. This, in turn, reduces the promotion of inflammatory responses, leading to effects such as myocardial cell damage, myocardial remodeling, and fibrosis. Ultimately, this helps protect the heart organ and contributes to the treatment of heart failure and related conditions.

Is Finerenone really safe?

From the information provided, it’s clear that finerenone offers numerous benefits. It not only improves chronic kidney disease related to type 2 diabetes but also demonstrates positive effects in the treatment of cardiovascular diseases. However, finerenone, like eplerenone, is a mineralocorticoid receptor antagonist, and safety is an important consideration.

Some researchers have conducted studies on the tolerability of mineralocorticoid receptor antagonists in heart failure. One such study is a phase IIb trial, a multicenter, randomized, double-blind clinical trial comparing finerenone to eplerenone.

These studies aim to assess the safety and efficacy of these medications in managing various conditions and understanding their potential side effects and interactions. The results of such trials help inform medical practice and ensure that patients receive safe and effective treatments.

This study included a total of 1,060 patients with reduced ejection fraction heart failure who also had type 2 diabetes or chronic kidney disease. These patients were treated with either finerenone or eplerenone. The five finerenone dosage groups began with oral doses of 2.5, 5, 7.5, 10, and 15 mg/day and were gradually increased to 5, 10, 15, 20, and 20 mg/day, respectively, by day 30.

The control group received eplerenone, starting with a dose of 25 mg every other day and gradually increased to 25 mg/day by day 30. By day 60, the eplerenone dose was increased to 50 mg/day, and both groups were reassessed at day 90.

The study results indicate that finerenone can lower serum biomarker levels in heart failure patients, improve predefined clinical outcomes in the study, and, compared to eplerenone, lead to a smaller increase in blood potassium levels, making it a safer option.

How to Find Affordable and Highly Effective finerenone

It’s widely known that the treatment for type 2 diabetes, RYBELSUS® (semaglutide) tablets, comes with a high cost of up to $995 for 30 tablets. Similarly, the medication for treating diabetic kidney disease, Kerendia finerenone tablets, can be as expensive as $670 for 30 tablets. The exorbitant prices of these medications undoubtedly add to the challenges faced by patients in their daily lives.

Is there an equally effective but more affordable medication available? The answer is LUCIFINE finerenone tablets produced by Lucius Pharmaceuticals. LUCIFINE finerenone tablets are a diabetes kidney disease treatment that has received approval from the Laotian Ministry of Health and is manufactured in Lucius Pharmaceuticals’ GMP factory in Laos, as approved by the U.S. FDA.

LUCIFINE finerenone tablets are not only a legitimately authorized medication but also come at a very affordable price, being only one-third the cost of Kerendia finerenone tablets while delivering the same efficacy.

DKD Care Center serves as the authoritative global distributor for LUCIFINE finerenone tablets, and we possess the necessary authorization certificates from Lucius Pharmaceuticals. The introduction of this new medication comes with significant discounts. If you have been suffering from diabetic kidney disease for an extended period, please don’t hesitate to contact us promptly:

Phone: +852 6993858

Whatsapp: +852 9506 4225



Leave a Reply

Your email address will not be published. Required fields are marked *